Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study

Norbert Gattermann, Carlo Finelli, Matteo Della Porta, Pierre Fenaux, Arnold Ganser, Agnes Guerci-Bresler, Mathias Schmid, Kerry Taylor, Dominique Vassilieff, Dany Habr, Gabor Domokos, Bernard Roubert, Christian Rose, L. Agaoglu, G. Alimena, D. Alonso, S. Ame, E. Angelucci, B. Arrizabalaga, M. Athanasiou-MetaxaB. Augustson, Y. Aydinok, A. Baba, M. Baccarani, J. Beck, P. Beris, O. Beyne-Rauzy, H. Birgens, D. Bordessoule, C. Borgna-Pignatti, A. Bosly, K. Bouabdallah, D. Bowden, D. Bowen, D. Bron, M. D. Cappellini, M. Capra, G. Cartron, M. Cazzola, C. Chalkias, L. L. Chan, S. Chancharunee, C. Chapman, P. Charoenkwan, E. Chasapopoulou, S. Cheze, A. Chuansumrit, P. Cianciulli, C. Dauriac, M. Delforge, G. Dölken, H. Dombret, J. Duyster, T. Economopoulos, G. Ehninger, M. Elalfy, A. El-Beshlawy, L. Enggaard, G. Fillet, A. Filosa, G. Forni, R. Galanello, G. Gastl, S. Giraudier, A. Goldfarb, A. Grigg, F. Gumruk, S. Y. Ha, D. Haase, B. Heinrich, M. Hertzberg, J. Ho, H. C. Hsu, S. Huang, M. Hunault-Berger, B. Inusa, D. Jaulmes, J. Jensen, A. Kattamis, Y. Kilinc, K. H. Kim, S. Kinsey, L. Kjeldsen, A. Koren, M. E. Lai, Y. Lai, J. W. Lee, K. H. Lee, S. H. Lee, L. Legros, C. Li, C. K. Li, Q. Li, K. H. Lin, W. Linkesch, M. Lübbert, D. Lutz, A. J. Mohamed Thalha, G. Mufti, P. Muus, F. Nobile, N. Papadopoulos, S. Perrotta, M. Petrini, M. Pfeilstöcker, A. Piga, J. Poole, J. B. Porter, E. Pungolino, G. Quarta, C. Ravoet, H. H. Jolimont Lobbes, A. F. Remacha, L. Roy, G. Saglio, G. Sanz, M. Schmugge, H. Schots, G. Secchi, J. F. Seymour, F. Shah, H. Shah, Z. Shen, B. Slama, P. Sutcharitchan, A. Taher, H. Tamary, H. J. Tesch, S. L. Thein, J. Troncy, A. Villegas, V. Viprakasit, L. Wainwright, B. Wassmann, M. Wettervald, A. Will, B. Wörmann, J. Wright, S. P. Yeh, S. S. Yoon, N. C. Zoumbos, S. Zweegman

Research output: Contribution to journalArticlepeer-review

Abstract

The prospective 1-year EPIC study enrolled 341 patients with myelodysplastic syndromes (MDS); although baseline iron burden was >2500. ng/mL, ∼50% were chelation-naïve. Overall median serum ferritin decreased significantly at 1 year (p=0.002). Decreases occurred irrespective of whether patients were chelation-naïve or previously chelated; changes were dependent on dose adjustments and ongoing iron intake. Sustained reductions in labile plasma iron were observed. Discontinuation rate (48.7%) and adverse event profile were consistent with previously reported deferasirox data in MDS. Alanine aminotransferase levels decreased significantly; change correlated significantly with reduction in serum ferritin (p

Original languageEnglish
Pages (from-to)1143-1150
Number of pages8
JournalLeukemia Research
Volume34
Issue number9
DOIs
Publication statusPublished - Sep 2010

Keywords

  • Deferasirox
  • Iron chelation therapy
  • Labile plasma iron
  • Myelodysplastic syndromes
  • Serum ferritin

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study'. Together they form a unique fingerprint.

Cite this